Latest Regulatory Approval News

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.

Bellavista Resources has successfully raised A$35 million through a two-tranche placement to fund its strategic acquisition and exploration plans in Canada and Australia.

Dalaroo Metals has mobilised its geological team to progress the Bongouanoa Gold Project in Côte d’Ivoire toward drill-ready status, leveraging promising historical gold intercepts and systematic fieldwork. The company is preparing for aircore and diamond drilling programs pending regulatory approvals.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

Pinnacle Investment Management reported an 11% drop in net profit after tax for the first half of FY26, despite record net inflows and a strategic move to fully acquire Pacific Asset Management.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Verity Resources is raising approximately $2 million through a non-renounceable entitlement offer to advance its Monument Gold and Botswana copper-silver projects, with directors backing the move through participation and underwriting.

Noronex Limited has exercised its option to acquire a 51% stake in the Etango North Uranium Project in Namibia, initiating a maiden drilling program backed by AI-driven exploration techniques.

Imricor Medical Systems has welcomed Oklahoma Heart Institute as the fourth U.S. site in its pivotal VISABL-AFL clinical trial, accelerating patient recruitment and the FDA approval pathway for its MRI-guided cardiac ablation technology.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.